Brokerage firm Deutsche Bank Maintains its rating on Opko Health(NYSE:OPK). In a research note issued to the investors, the brokerage major Lowers the price-target to $10.00 per share. The shares have been rated Hold. The rating by Deutsche Bank was issued on Jun 16, 2016.
In a different note, Standpoint Research said it Initiates Coverage on Opko Health, according to a research note issued on Jun 3, 2016. The shares have been rated ‘Buy’ by the firm. On Mar 31, 2016, Barrington Research said it Maintains its rating on Opko Health. In the research note, the firm Lowers the price-target to $17.00 per share. The shares have been rated ‘Outperform’ by the firm.
Opko Health (OPK) made into the market gainers list on Tuesdays trading session with the shares advancing 5.55% or 0.51 points. Due to strong positive momentum, the stock ended at $9.7, which is also near the day’s high of $9.99. The stock began the session at $9.97 and the volume stood at 1,13,70,687 shares. The 52-week high of the shares is $17.51 and the 52 week low is $7.1225. The company has a current market capitalization of $5,310 M and it has 54,74,44,350 shares in outstanding.
Opko Health(OPK) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $291.00M. Analysts had an estimated revenue of $266.30M. Earnings per share were $-0.02. Analysts had estimated an EPS of $-0.03.
Several Insider Transactions has been reported to the SEC. On Jun 15, 2016, Gamma Investments Trust Frost (CEO) purchased 16,000 shares at $9.00 per share price.Also, On May 17, 2016, Robert A Baron (director) sold 37,500 shares at $9.83 per share price.On Mar 18, 2016, Jane Ph D Hsiao (Vice Chairman & CTO) purchased 1,200 shares at $10.65 per share price, according to the Form-4 filing with the securities and exchange commission.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.